Barclays PLC boosted its holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) by 352.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,696 shares of the company's stock after buying an additional 62,073 shares during the period. Barclays PLC owned approximately 0.13% of Treace Medical Concepts worth $460,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also bought and sold shares of TMCI. Quarry LP bought a new position in shares of Treace Medical Concepts in the third quarter worth $38,000. HighTower Advisors LLC purchased a new position in Treace Medical Concepts during the 3rd quarter valued at about $58,000. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Treace Medical Concepts by 243.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,613 shares of the company's stock valued at $62,000 after buying an additional 7,522 shares during the period. Palumbo Wealth Management LLC purchased a new stake in shares of Treace Medical Concepts in the third quarter worth about $75,000. Finally, Walleye Capital LLC bought a new position in shares of Treace Medical Concepts in the third quarter valued at approximately $75,000. Institutional investors own 84.08% of the company's stock.
Treace Medical Concepts Trading Up 5.6 %
Shares of NASDAQ:TMCI traded up $0.46 during trading on Friday, reaching $8.71. 391,872 shares of the company traded hands, compared to its average volume of 212,646. The business's fifty day moving average is $7.77 and its 200-day moving average is $6.70. Treace Medical Concepts, Inc. has a 52-week low of $3.92 and a 52-week high of $15.98. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $542.63 million, a price-to-earnings ratio of -8.80 and a beta of 0.69.
Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The firm had revenue of $45.09 million during the quarter, compared to the consensus estimate of $43.48 million. Treace Medical Concepts had a negative net margin of 30.33% and a negative return on equity of 51.12%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.28) earnings per share. As a group, analysts forecast that Treace Medical Concepts, Inc. will post -0.92 EPS for the current year.
Analyst Ratings Changes
A number of research firms recently weighed in on TMCI. Stifel Nicolaus upped their target price on shares of Treace Medical Concepts from $7.00 to $8.00 and gave the stock a "hold" rating in a report on Wednesday, November 6th. Truist Financial boosted their target price on Treace Medical Concepts from $7.00 to $8.40 and gave the stock a "hold" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $8.00 price target on shares of Treace Medical Concepts in a report on Tuesday, December 17th. Finally, Lake Street Capital initiated coverage on Treace Medical Concepts in a report on Tuesday, December 31st. They set a "buy" rating and a $14.50 price objective for the company. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $8.98.
Read Our Latest Stock Report on TMCI
Treace Medical Concepts Company Profile
(
Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Further Reading
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
